CDKN2A and neoplasm: EPCs and EPs are generally heterogeneous tumor entities, but there are also distinct discrepancies between them, such as exclusive TP53, NCOR1, and CDKN2A mutations in EPCs and a higher mutational load in EPCs than in EPs.